Genprex, Inc. (GNPX) Financials

GNPX

FY2025 annual

Revenue Not reported for FY2025

Net Income -$16.2M YoY not available

EPS (Diluted) Not reported for FY2025

Operating Cash Flow -$15.3M +14.6% YoY

Market Cap $1.7M as of Oct 17, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.1x on $14.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GNPX SEC filings page.

This page shows Genprex, Inc. (GNPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GNPX FY2025 2026-10-01

Genprex remains a development-stage business: no valid revenue is reported, while research spending and external financing fund operations.

In FY2025, operating cash flow of -$15.3M nearly matched the net loss of $16.2M, indicating that reported losses were largely cash-consuming rather than dominated by noncash charges. This agreement between earnings and cash flow makes the latest loss a useful measure of current resource use, despite the absence of revenue.

The cost structure is development-led: research and development was $9.4M versus selling, general and administrative expense of $6.1M in FY2025. With no valid revenue reported, spending is supporting the development effort rather than being absorbed by a commercial sales base.

The balance sheet was rebuilt between FY2024 and FY2025: total assets rose from $4.1M to $10.2M. Liabilities fell to $2.2M while FY2025 financing supplied $21.5M, indicating that capitalization improved through new funding rather than operating earnings.

Financial Health Signals

Financial health score not available

Genprex, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/5

Genprex, Inc. passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Genprex, Inc. reported a net loss of $16.2M while operations used $15.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$4.4M

YoY+4.9%

QoQ+0.3%

Genprex, Inc. reported -$4.4M in net income in Q2 2026. This represents an increase of 4.9% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$15.2M

YoY+1025.2%

QoQ-16.0%

5Y CAGR-19.3%

Genprex, Inc. held $15.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

819,709

5Y CAGR-55.6%

Genprex, Inc. had 819,709 shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-30.1%

YoY+306.0pp

QoQ-3.7pp

Genprex, Inc.'s ROE was -30.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 306.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.7M

YoY+7.4%

QoQ-2.3%

Genprex, Inc. invested $2.7M in research and development in Q2 2026. This represents an increase of 7.4% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

GNPX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GNPX quarterly income statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	N/A	N/A	$0	$0	$0	$0	$0	N/A	$0	$0	$0
R&D Expenses	N/A	$9.4M-10.5%	$10.5M-40.2%	$17.6M+53.1%	$11.5M+28.3%	$9.0M+22.8%	$7.3M+271.3%	$2.0M+102.5%	$971K+235.1%	$290K-18.3%	$355K
SG&A Expenses	N/A	$6.1M-42.7%	$10.6M-20.8%	$13.4M+9.2%	$12.3M+5.3%	$11.7M+9.8%	$10.6M+22.2%	$8.7M-23.6%	$11.4M+277.1%	$3.0M-20.1%	$3.8M
Operating Income	N/A	-$15.5M	N/A	-$31.1M-30.3%	-$23.8M-15.3%	-$20.7M-15.1%	-$18.0M-68.1%	-$10.7M+13.6%	-$12.4M-273.3%	-$3.3M+19.8%	-$4.1M
EBITDA	N/A	-$15.5M+23.9%	-$20.4M+34.3%	-$31.0M-30.4%	-$23.8M-15.3%	-$20.6M-15.1%	-$17.9M-68.1%	-$10.7M+13.7%	-$12.4M-273.4%	-$3.3M+19.9%	-$4.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$38K+1909.6%	$2K	$0
Income Tax	N/A	$0-100.0%	$3K	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$16.2M	N/A	-$30.9M-30.0%	-$23.7M-14.9%	-$20.7M-15.2%	-$17.9M-68.4%	-$10.7M+13.9%	-$12.4M-273.3%	-$3.3M+19.8%	-$4.1M
EPS (Basic)	N/A	-$17.40+93.5%	-$266.89-1083.0%	-$22.56-13.9%	-$19.80-4400.0%	-$0.44	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$2.7M+7.4%	$2.7M+8.1%	N/A	$2.2M-20.4%	$2.5M+50.0%	$2.5M-22.4%	N/A	$2.8M-40.3%
SG&A Expenses	$1.8M-17.5%	$1.7M+22.3%	N/A	$1.2M-26.4%	$2.2M-55.0%	$1.4M-47.4%	N/A	$1.6M-50.5%
Operating Income	-$4.5M+4.2%	-$4.5M-13.2%	N/A	-$3.3M+22.6%	-$4.7M+28.2%	-$4.0M+33.8%	N/A	-$4.3M+44.5%
EBITDA	N/A	-$4.5M-13.2%	N/A	-$3.3M+22.6%	-$4.7M+28.1%	-$4.0M+33.8%	N/A	-$4.3M+44.5%
Net Income	-$4.4M+4.9%	-$4.5M-12.5%	N/A	-$3.8M+12.0%	-$4.7M+28.0%	-$4.0M+33.6%	N/A	-$4.3M+44.3%
EPS (Basic)	-$9.40-4972.9%	-$0.64+95.1%	$5.60-92.8%	-$5.00+91.9%	-$0.19+93.8%	-$12.98-236.3%	$78.03+453.2%	-$61.65-1050.2%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax, EPS (Diluted), Diluted Shares (Avg).

GNPX Balance Sheet

GNPX quarterly balance sheet

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$10.2M+146.3%	$4.1M-61.3%	$10.7M-57.5%	$25.1M-41.5%	$42.9M+36.6%	$31.4M+787.5%	$3.5M-61.9%	$9.3M+635.9%	$1.3M-34.1%	$1.9M
Current Assets	$8.4M+302.3%	$2.1M-72.4%	$7.5M-64.9%	$21.5M-45.1%	$39.1M+41.3%	$27.7M+830.7%	$3.0M-66.4%	$8.8M+4470.4%	$194K-88.2%	$1.6M
Cash & Equivalents	$7.8M+388.9%	$1.6M-76.2%	$6.7M-67.8%	$21.0M-45.8%	$38.6M+41.4%	$27.3M+1264.3%	$2.0M-76.7%	$8.6M+5233.9%	$161K-89.9%	$1.6M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	$0-100.0%	$35K	$0-100.0%	$127	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.2M-12.3%	$2.5M-23.0%	$3.3M+15.8%	$2.8M+77.3%	$1.6M+251.7%	$451K-11.7%	$511K+31.7%	$388K-53.3%	$831K+190.9%	$286K
Current Liabilities	$2.2M-13.2%	$2.5M-23.0%	$3.3M+15.8%	$2.8M+77.3%	$1.6M+251.7%	$451K-11.7%	$511K+31.7%	$388K-53.3%	$831K+190.9%	$286K
Non-Current Liabilities	$23K	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$8.0M+391.4%	$1.6M-78.2%	$7.4M-66.7%	$22.3M-46.0%	$41.3M+33.5%	$30.9M+922.5%	$3.0M-66.0%	$8.9M+1972.3%	$429K-73.6%	$1.6M
Retained Earnings	-$171.0M-10.5%	-$154.8M-15.8%	-$133.7M-30.0%	-$102.8M-30.0%	-$79.1M-35.4%	-$58.4M-44.3%	-$40.5M-35.7%	-$29.8M-70.9%	-$17.5M-23.4%	-$14.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$17.1M+347.7%	$20.3M+237.9%	$10.2M+146.3%	$3.6M-8.8%	$3.8M-42.0%	$6.0M-52.2%	$4.1M-61.3%	$3.9M-76.5%
Current Assets	$15.8M+670.5%	$18.8M+351.6%	$8.4M+302.3%	$1.7M-10.6%	$2.1M-53.2%	$4.2M-54.9%	$2.1M-72.4%	$1.9M-85.1%
Cash & Equivalents	$15.2M+1025.2%	$18.0M+420.4%	$7.8M+388.9%	$1.1M-25.9%	$1.3M-45.2%	$3.5M-57.8%	$1.6M-76.2%	$1.5M-87.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.3M-3.9%	$3.4M+57.6%	$2.2M-12.3%	$2.8M+24.6%	$2.4M+7.8%	$2.1M-43.8%	$2.5M-23.0%	$2.2M-48.3%
Current Liabilities	$2.3M-3.9%	$3.4M+56.6%	$2.2M-13.2%	$2.6M+13.8%	$2.4M+7.8%	$2.1M-43.8%	$2.5M-23.0%	$2.2M-48.3%
Non-Current Liabilities	$0+100.0%	$23K	$23K	$243K	-$2-300.0%	$0	$0	$0+100.0%
Total Equity	$14.8M+963.5%	$16.9M+337.7%	$8.0M+391.4%	$768K-53.9%	$1.4M-68.0%	$3.9M-55.8%	$1.6M-78.2%	$1.7M-86.5%
Retained Earnings	-$179.9M-10.1%	-$175.5M-10.5%	-$171.0M-10.5%	-$167.2M-11.1%	-$163.4M-11.8%	-$158.8M-13.7%	-$154.8M-15.8%	-$150.5M-17.8%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

GNPX Cash Flow Statement

GNPX quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$15.6M	-$15.3M+14.6%	-$17.9M+27.6%	-$24.7M-40.4%	-$17.6M-23.4%	-$14.3M-2.5%	-$13.9M-101.4%	-$6.9M-1.1%	-$6.8M-215.3%	-$2.2M-74.0%	-$1.2M
Depreciation & Amortization	N/A	$0-100.0%	$780K+5099.8%	$15K-41.3%	$26K+13.5%	$23K-1.1%	$23K+74.3%	$13K+122.1%	$6K+81.5%	$3K+276.1%	$862
Stock-Based Compensation	N/A	$300K-90.9%	$3.3M-38.9%	$5.4M+14.3%	$4.7M-11.5%	$5.3M+25.9%	$4.2M+20.3%	$3.5M-35.1%	$5.4M+310.6%	$1.3M-50.2%	$2.7M
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$32K+80.5%	$18K-47.4%	$33K+48.7%	$22K+281.0%	$6K+18.3%	$5K
Free Cash Flow	N/A	N/A	N/A	N/A	-$17.6M-23.1%	-$14.3M-2.6%	-$14.0M-100.7%	-$7.0M-1.2%	-$6.9M-215.5%	-$2.2M-73.7%	-$1.3M
Investing Cash Flow	N/A	$0-100.0%	$775K+1187.8%	-$71K-19.2%	-$60K+28.7%	-$84K+96.4%	-$2.3M-146.8%	-$947K-816.5%	-$103K-62.9%	-$63K+29.2%	-$90K
Financing Cash Flow	$29.4M	$21.5M+79.3%	$12.0M+13.4%	$10.6M+164751.8%	$6K-100.0%	$25.7M-38.3%	$41.6M+3182.0%	$1.3M-91.8%	$15.4M+1838.3%	$794K-70.7%	$2.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$5.1M-33.0%	-$3.1M+24.6%	-$4.1M-5.9%	-$3.2M-45.8%	-$3.9M+41.2%	-$4.2M+21.5%	-$3.9M+22.0%	-$2.2M+53.8%
Depreciation & Amortization	N/A	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$463-86.5%	$1K-65.8%
Stock-Based Compensation	$68K-85.1%	$119K-35.6%	N/A	$20K-95.3%	$459K-77.9%	$184K-64.3%	N/A	$420K
Investing Cash Flow	N/A	N/A	$0+100.0%	$0	$0-100.0%	$0+100.0%	-$1+100.0%	$0+100.0%
Financing Cash Flow	$2.2M+28.7%	$13.4M+121.6%	$10.8M+171.8%	$2.9M+142.2%	$1.7M+8293.9%	$6.0M-11.3%	$4.0M+99570150.0%	$1.2M-81.3%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

GNPX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GNPX quarterly financial ratios

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Return on Equity	-203.8%	N/A	-416.1%-309.5pp	-106.6%-56.5pp	-50.1%+8.0pp	-58.0%+294.3pp	-352.4%-213.1pp	-139.3%+634.0pp	-773.3%-519.0pp	-254.3%
Return on Assets	-159.8%	N/A	-289.2%-194.6pp	-94.6%-46.4pp	-48.2%+9.0pp	-57.2%+244.3pp	-301.5%-168.0pp	-133.5%+129.6pp	-263.1%-46.8pp	-216.3%
Current Ratio	3.84+3.0x	0.83-1.5x	2.31-5.3x	7.64-17.0x	24.69-36.8x	61.47+55.6x	5.83-17.0x	22.81+22.6x	0.23-5.5x	5.74
Debt-to-Equity	0.28-1.3x	1.55+1.1x	0.44+0.3x	0.13+0.1x	0.040.0x	0.01-0.2x	0.17+0.1x	0.04-1.9x	1.94+1.8x	0.18
Asset Turnover	N/A	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A	0.000.0x	0.000.0x	0.00

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-30.1%+306.0pp	-26.4%+76.1pp	N/A	-494.8%-235.6pp	-336.0%-186.6pp	-102.5%-34.3pp	N/A	-259.2%-196.3pp
Return on Assets	-25.9%+96.2pp	-22.0%+44.0pp	N/A	-106.6%+3.8pp	-122.1%-23.8pp	-66.0%-18.5pp	N/A	-110.5%-63.9pp
Current Ratio	6.77+5.9x	5.61+3.7x	3.84+3.0x	0.67-0.2x	0.84-1.1x	1.94-0.5x	0.83-1.5x	0.86-2.1x
Debt-to-Equity	0.16-1.6x	0.20-0.4x	0.28-1.3x	3.64+2.3x	1.75+1.2x	0.55+0.1x	1.55+1.1x	1.35+1.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Genprex, Inc. GNPX	FY2025	N/A	-$16.2M	N/A	$1.7M	—
IN8bio, Inc. INAB	FY2025	N/A	-$19.4M	N/A	$10.9M	—
Kiora Pharmaceuticals, Inc. KPRX	FY2025	$0	-$11K	N/A	$10.6M	—
Creative Medical Technology Holdings, Inc. CELZ	FY2025	$6K	-$6.0M	N/A	$5.6M	—
Calidi Biotherapeutics, Inc. CLDI	FY2025	N/A	-$19.9M	N/A	$2.2M	—
TransCode Therapeutics, Inc. RNAZ	FY2025	N/A	-$34.7M	N/A	$28.8M	—

Where Genprex, Inc. Ranks

Frequently Asked Questions

Is Genprex, Inc. profitable?

No, Genprex, Inc. (GNPX) reported a net income of -$16.2M in fiscal year 2025.

What is Genprex, Inc.'s EBITDA?

Genprex, Inc. (GNPX) had EBITDA of -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Genprex, Inc.'s return on equity (ROE)?

Genprex, Inc. (GNPX) has a return on equity of -203.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Genprex, Inc.'s operating cash flow?

Genprex, Inc. (GNPX) recorded an outflow of $15.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Genprex, Inc.'s total assets?

Genprex, Inc. (GNPX) had $10.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Genprex, Inc. spend on research and development?

Genprex, Inc. (GNPX) invested $9.4M in research and development during fiscal year 2025.

How many shares does Genprex, Inc. have outstanding?

Genprex, Inc. (GNPX) had 9M shares outstanding as of fiscal year 2025.

What is Genprex, Inc.'s current ratio?

Genprex, Inc. (GNPX) had a current ratio of 3.84 as of fiscal year 2025, which is generally considered healthy.

What is Genprex, Inc.'s debt-to-equity ratio?

Genprex, Inc. (GNPX) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Genprex, Inc.'s return on assets (ROA)?

Genprex, Inc. (GNPX) had a return on assets of -159.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Genprex, Inc.'s P/E ratio?

Genprex, Inc. (GNPX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.7M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Genprex, Inc.'s price-to-sales ratio?

Genprex, Inc. (GNPX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.7M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Genprex, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Genprex, Inc. (GNPX) held $7.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.3M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Genprex, Inc.'s Piotroski F-Score?

Genprex, Inc. (GNPX) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Genprex, Inc.'s earnings high quality?

Genprex, Inc. (GNPX) reported a net loss of $16.2M while operations used $15.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.